InflaRx develops new therapeutics in the field of acute and chronic inflammation and consists of a team of internationally recognized researchers and clinicians who have dedicated their careers to translate discoveries and expertise into new therapeutic concepts for clinical application.

TypePublic
HQJena, DE
Founded2006
Size (employees)9 (est)
Websiteinflarx.com
InflaRx was founded in 2006 and is headquartered in Jena, DE
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

InflaRx Office Locations

InflaRx has offices in Planegg and Jena
Planegg, DE
5 Semmelweisstraße
Show all (2)
Report incorrect company information

InflaRx Financials and Metrics

InflaRx Revenue

InflaRx's revenue was reported to be €108 k in FY, 2017 which is a 53.2% decrease from the previous period.
EUR

Revenue (FY, 2017)

108.0k

Revenue growth (FY, 2016 - FY, 2017), %

(53.2%)

Net income (FY, 2017)

(24.2m)

EBIT (FY, 2017)

(19.4m)

Market capitalization (15-Oct-2018)

834.3m

Closing stock price (15-Oct-2018)

32.5

Cash (31-Dec-2017)

123.3m
InflaRx's current market capitalization is $834.3 m.
EURFY, 2015FY, 2016FY, 2017

Revenue

134.0k231.0k108.0k

Revenue growth, %

72%(53%)

General and administrative expense

438.0k1.8m5.1m

R&D expense

3.5m5.3m14.4m
EURFY, 2015FY, 2016FY, 2017

Cash

3.3m29.1m123.3m

Current Assets

3.5m29.4m124.0m

PP&E

109.0k131.0k173.0k

Total Assets

3.6m29.5m124.2m
EURFY, 2015FY, 2016FY, 2017

Net Income

(4.9m)(8.9m)(24.2m)

Depreciation and Amortization

40.0k33.0k71.0k

Cash From Operating Activities

(3.3m)(5.0m)(12.2m)

Cash From Investing Activities

(13.0k)(53.0k)(167.0k)
EURY, 2017

Revenue/Employee

12.0k

Financial Leverage

1 x

P/E Ratio

(12.5)
Show all financial metrics
Report incorrect company information

InflaRx News and Updates

InflaRx N.V. Announces Appointment of Jens Holstein to Board of Directors

JENA, Germany, Sept. 21, 2018 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company developing innovative therapeutics to treat life-threatening and devastating inflammatory diseases by targeting the complement system, a key component of the innate immune system, announced t…

InflaRx N.V. Reports Second Quarter 2018 Financial & Operating Results

JENA, Germany, Aug. 09, 2018 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company developing innovative therapeutics to treat life-threatening inflammatory diseases by targeting the complement system, a key component of the innate immune system, reported financial and opera…
Report incorrect company information

InflaRx Company Life and Culture

Report incorrect company information